Australia Health

LTR Pharma (ASX:LTP) completed its final Phase 2 clinical report, confirming that its nasal spray achieved peak blood concentration in 10 minutes.

Imagion Biosystems (ASX:IBX) has secured central Institutional Review Board ethics approval from Advarra for its Phase 1b/2 clinical trial.

Telix Pharmaceuticals (ASX:TLX) announced that the U.S. Food and Drug Administration granted a Fast Track designation for its BiPASS prostate cancer imaging programme.

Neuren Pharmaceuticals (ASX:NEU) announced partner Acadia Pharmaceuticals (NASDAQ:ACAD) secured a US patent allowance extending trofinetide protections.

Memphasys (ASX:MEM) has executed a convertible note subscription agreement with Peters Investments to secure a $3.5 million.

Firebrick Pharma (ASX:FRE) has approved a comprehensive strategic plan to enter the US retail pharmacy market with its Nasodine product range.

Argent BioPharma (ASX:RGT) has executed an exclusive licence agreement with NLC to commercialise its Tollovir, Tollovid, and NutraVir antiviral applications globally outside of China.

Mayne Pharma (ASX:MYX) agreed to pay US$0.7 million to settle a civil complaint filed by attorneys general from 49 US states and territories.

AFT Pharmaceuticals (ASX:AFP) entered an exclusive license and supply agreement with Mikasa Seiyaku to commercialise its pain treatment Maxigesic IV in Japan.

Memphasys (ASX:MEM) has identified an expedited 510(k) pathway to seek clearance for its Felix Sperm Separation System.

Nexsen (ASX:NXN) has entered into a non-binding term sheet with FlashDx Shenzhen to set up a 50:50 joint venture.

Healius (ASX:HLS) entered into a binding agreement to sell its subsidiary Agilex Biolabs for an enterprise value of $160 million.